SCHEMBL17386255

SCHEMBL17386255

COC(=O)c1ccc(C=CCc2cccc(OC)c2)c(Br)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ HDAC1 Q13547 2/20 0.45
▸ MAPT P10636 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ HPGD P15428 2/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ POLB P06746 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ MMP13 P45452 1/20 0.43
▸ NOTUM Q6P988 1/20 0.42
▸ P4HB P07237 1/20 0.42
▸ TP53 P04637 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ HDAC8 Q9BY41 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17386254 1.00 LMNA (0.45) LMNANPC1RAB9AHDAC1MAPT
SCHEMBL17429644 0.90 NOTUM (0.45) RAB9AMAPTSMN1; SMN2NOTUMP4HB
SCHEMBL17385993 0.86 NOTUM (0.42) LMNANPC1RAB9AHDAC1MAPT
SCHEMBL17385992 0.86 NOTUM (0.42) LMNANPC1RAB9AHDAC1MAPT
SCHEMBL17429650 0.82 NOTUM (0.47) MAPTHTTHPGDNOTUMP4HB
SCHEMBL17386069 0.74 HDAC1 (0.53) LMNAHDAC1HPGDP4HBMEN1
SCHEMBL8325287 0.74 ALDH1A1 (0.55) LMNAHPGDSMN1; SMN2POLBP4HB
SCHEMBL8325284 0.74 ALDH1A1 (0.55) LMNAHPGDSMN1; SMN2POLBP4HB
SCHEMBL17978233 0.72 CYP1A1 (0.53) LMNANPC1RAB9AMAPTHTT
SCHEMBL19810852 0.72 CYP1A1 (0.53) LMNANPC1RAB9AMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108017603-B Tricyclic compounds and uses thereof 株式会社蒂奥姆生物 2021-07-23 — — CN disclosed
EP-2963027-B1 TRICYCLIC COMPOUND AND USE THEREOF TIUMBIO CO LTD (KR) 2018-12-26 — — EP disclosed
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 — — US disclosed
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF SK CHEMICALS CO., LTD. (KR) 2016-01-14 — — US disclosed
EP-2963027-A1 TRICYCLIC COMPOUND AND USE THEREOF SK Chemicals Co., Ltd. (KR) 2016-01-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF GPR65, GPR119, GPR35 LMNA 2845/4885NPC1 223/4885RAB9A 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback